Loading...
Market
Will REC-1245 reach the primary endpoint of Phase I/II clinical trial by December 31, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial results published by Recursion Pharmaceuticals or FDA announcements
Story
Recursion's AI-Derived REC-1245 Gets FDA Clearance; First-in-Class RBM39 Degrader for Solid Tumors, Lymphoma
Oct 2, 2024, 12:20 PM
Recursion Pharmaceuticals (RXRX) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for REC-1245, a potential first-in-class RBM39 degrader intended for biomarker-enriched solid tumors and lymphoma. This marks the company's first program to combine its end-to-end suite of AI-enabled active learning modules, moving from target identification to IND enabling studies in under 18 months, more than twice as fast as industry standards. The FDA clearance paves the way for Recursion to initiate a Phase I/II clinical trial of REC-1245.
View original story
Similar markets
Yes • 50%
No • 50%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
